Lantern Pharma Q1 2026 Earnings Report

Lantern Pharma EPS Results

• Actual EPS: -$0.30
• Consensus EPS: -$0.36
• Beat/Miss: Beat by +$0.06
• One Year Ago EPS: N/A

Lantern Pharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Lantern Pharma Announcement Details

• Quarter: Q1 2026
• Date: 5/15/2026
• Time: After Market Closes
• Conference Call Date: Friday, May 15, 2026
• Conference Call Time: 4:00PM ET

Lantern Pharma (NASDAQ:LTRN), Inc. is a clinical-stage biopharmaceutical company focused on using artificial intelligence, machine learning and genomic data to discover and develop precision cancer therapies. The company’s approach is designed to identify patient populations most likely to respond to a therapy, with the goal of improving drug-development efficiency and treatment outcomes.

Lantern’s technology platform, known as RADR, analyzes large datasets from clinical studies, scientific literature and other sources to support drug discovery, biomarker identification and clinical-trial design. The company applies this platform to both internally developed drug candidates and potential opportunities involving existing or previously investigated oncology compounds.

Lantern has advanced a pipeline of investigational therapies intended to address cancers with significant unmet medical needs, including certain solid tumors and blood cancers. Its programs are in various stages of preclinical and clinical development, and the company’s operations and clinical activities are primarily centered in the United States.

Founded in 2013 and headquartered in Austin, Texas, Lantern became a publicly traded company in 2020. Panna Sharma serves as the company’s chief executive officer and is a member of its board of directors.